IA; Economía; Energía; Derechos Trans; she/her

Chile
Joined August 2018
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
Replying to @JuneDoe2fug
Una hermana ayuda a otra hermana ❣️
14
Replying to @j4la4b
El trío Anthropic, SpaceX y Alphabet tienen contratos cruzados y la última es accionista de las dos primeras, Google tiene para regodearse y tomar las cosas con calma e investigar modelos internos sin necesidad de lanzar al público.
44
María Josefa GK 🏳️‍⚧️ retweeted
40
131
1,155
5,610
Pedazo de álbum se sacó Wage War
1
75
Replying to @ErickSky
El trío Anthropic, SpaceX y Alphabet van a ganar la carrera de la IA, los contratos cruzados y participaciones en el capital de Alphabet en Anthropic y SpaceX señalan la dirección
1
82
The prettiest little set🎀
2
1
42
604
María Josefa GK 🏳️‍⚧️ retweeted
Las elecciones de israel es esto ehh
16
583
6
11,895
61,104
María Josefa GK 🏳️‍⚧️ retweeted
• SpaceX set to be largest VR200 buyer in 2027E (20k racks on 30k+ demand / ~10GW) Wow
Summary of Robust VR200 Outlook 
📈NVL72 rack TAM: 73k / 96k in 2026E/2027E • Vera Rubin ramping with 85%+ first-pass yield; further acceleration expected in 1Q27
• 2026E: 67k GB200/GB300 + 6k VR200
• 2027E: VR200 + initial VR300 (Ultra) drive most of the growth (86k units)
• SpaceX set to be largest VR200 buyer in 2027E (20k racks on 30k+ demand / ~10GW)
• Major 6 neoclouds (SpaceX + CoreWeave + tier-2s) to take 19k/34k racks (27%/35% of industry)
• CoreWeave near-term funding risk viewed as manageable Vendor dynamics
• Hon Hai winning bigger SpaceX allocation (model 40-45%) + share gains at Google/Meta
• Pegatron limited; DELL/Wistron face share pressure Recommendations
• Hon Hai (2317 TT) Buy – rising SpaceX + CSP share
 #VR200 #NVL72 #AIServer #Neocloud #HonHai #Lenovo
26
23
9
479
74,301
SK Hynix sorprende en sus resultados del Q3 y menciona que el mercado mundial de memoria(RAM) seguirá tensionado por una demanda sobrepasando la oferta hasta 2030(misma apreciación que hizo Micron en sus resultados trimestrales).
1
281
María Josefa GK 🏳️‍⚧️ retweeted
SK HYNIX $SKHY Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $78.9B (Est. $74.8B) 🟢; +328% YoY 🔹 Oper Profit: $62.8B (Est. $58.5B) 🟢; +632% YoY 🔹 Oper Margin: 80%; +3,300 bps YoY; record high 🔹 QoQ: Revenue +32% / Oper Profit +38% Q4 Guide: 🔹 DRAM Bit Growth: Mid-20% QoQ 🔹 NAND Bit Growth: Mid-single% QoQ incl. Solidigm Q3 Pricing & Volume: 🔹 DRAM ASP: High-20% QoQ; bits ~+10% QoQ 🔹 NAND ASP: Mid-20% QoQ; bits slightly lower QoQ Profitability: 🔹 Gross Margin: 85.7% (Est. 85.2%) 🟢 🔹 EBITDA: $66.1B; 84% margin; +486% YoY 🔹 EPS: $41.07; +205% YoY Financials: 🔹 Cash: $86.3B; +311% YoY 🔹 Interest-Bearing Debt: $11.9B; -34% YoY 🔹 Net Debt-to-Equity: -32%; -2,800 bps YoY 🔹 Operating Cash Flow: $41.3B; +281% YoY 🔹 Total Assets: $295.5B 2027 Market Outlook: 🔹 DRAM Demand Bit Growth: +mid-20% YoY 🔹 NAND Demand Bit Growth: +high-teens% YoY 🔹 2027 CapEx: To rise significantly vs 2026 🔸 Memory demand expected to outpace supply through 2030 Product & Technology: 🔹 HBM4: Expected to surpass HBM3E in HBM shipment and revenue share in Q4 🔹 2027 HBM: Negotiations finalized; profitability gap with conventional DRAM expected to narrow meaningfully 🔹 M15X: Ramp-up accelerating to full capacity by end-2026 🔹 321L NAND: Over 50% of domestic capacity in Q4 Business Highlights: 🔹 LTAs: Signed with 14 key customers incl. major global CSPs; standard 5-year term; over 50% of 2027-2028 capacity secured 🔹 Q3 Dividend: ~₩20,000/share (~$15.08), incl. a ₩10,000 special dividend from realized Kioxia gains 🔹 Share Acquisition: ₩20T (~$15.1B) for the quarter, incl. ~₩10T for executive & employee compensation 🔸 Quarterly revenue topped ₩100T for the first time Note: 🔹 Net Profit: $30.0B; +216% YoY 🔸 Includes a $24.6B non-operating loss: a $17.3B investment-asset loss and an $8.8B FX loss as the won strengthened FX used for USD conversion: $1 = ₩1,326 (mid-market; Oct 27, 2026)
109
349
205
2,280
463,419
IA aplicada al desarrollo de medicamentos, la era que estamos iniciando es una locura.
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. anthropic.com/research/early…
4
342
Replying to @j4la4b
A rezarle al Taita Dios para que nada malo ocurra este verano.
1
23
Replying to @j4la4b
Y gran parte del empleo es sostenido por los medianos y chicos 💀
1
103
Replying to @j4la4b
Que terrible que han pasado meses desde que asumió el Gobierno y no he visto algún plan para rescatar la industria forestal.
1
1
121